Goldman Sachs Downgrades Idenix Pharmaceuticals (IDIX) to Sell
IDIX Hot Sheet
Rating Summary:5 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Goldman Sachs downgrades Idenix Pharmaceuticals (Nasdaq: IDIX) from Neutral to Sell.
To see more analyst ratings on IDIX Click Here.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
To see more analyst ratings on IDIX Click Here.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Goldman Sachs Downgrades Raytheon (RTN) to Sell; Risk To Back-End Loaded 2012
- JPMorgan Downgrades Heinz (HNZ) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
